VenatoRx Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference

MALVERN, Pa.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/Enterobacteriaceae?src=hash” target=”_blank”gt;#Enterobacteriaceaelt;/agt;–VenatoRx
Pharmaceuticals
, a world leader in antibacterial and antiviral drug
research and development, announced that its Chief Business Officer, Tony
Meehan, MBA, PhD
, will present at the 2019
BIO CEO & Investor Conference
.

Presentation Details:
Date: Monday,
February 11, 2019
Time: 3:30pm ET
Location: New York Marriott
Marquis (Gramercy room)

About VenatoRx Pharmaceuticals, Inc.

VenatoRx is a private pharmaceutical company that is focused on the
discovery and development of novel anti-infectives to treat
multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral
infections. VenatoRx’s lead product, VNRX-5133, is an injectable
broad-spectrum beta-lactamase inhibitor (BLI) that directly inhibits all
four Ambler classes of beta-lactamases. In addition, VenatoRx has a
broad pipeline of preclinical programs, including a broad-spectrum
orally bioavailable BLI, a novel class of Penicillin-Binding Protein
(PBP) inhibitors that are impervious to beta-lactamase-driven
resistance, and novel antiviral agents. For more information, please
visit www.venatorx.com.

Contacts

Heather Hunter
Vice President, Communications
VenatoRx
Pharmaceuticals, Inc.
hunter@venatorx.com
610.644.8935
x8327

error: Content is protected !!